Ichiro M Omori

Summary

Affiliation: Yokkaichi Social Insurance Hospital
Country: Japan

Publications

  1. pmc Can pill placebo augment cognitive-behavior therapy for panic disorder?
    Toshi A Furukawa
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    BMC Psychiatry 7:73. 2007
  2. doi request reprint Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis
    I M Omori
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    J Psychopharmacol 23:539-50. 2009
  3. doi request reprint Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis
    Norio Watanabe
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya, Japan
    CNS Drugs 24:35-53. 2010
  4. ncbi request reprint Mirtazapine versus other antidepressive agents for depression
    Norio Watanabe
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho cho, Mizuho ku, Nagoya, Aichi, Japan, 467 8601
    Cochrane Database Syst Rev 12:CD006528. 2011
  5. ncbi request reprint Fluvoxamine versus other anti-depressive agents for depression
    Ichiro M Omori
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya, Japan, 467 8601
    Cochrane Database Syst Rev 3:CD006114. 2010

Detail Information

Publications5

  1. pmc Can pill placebo augment cognitive-behavior therapy for panic disorder?
    Toshi A Furukawa
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    BMC Psychiatry 7:73. 2007
    ..Whether psychotherapy plus pill placebo is the same as psychotherapy alone is an empirical question which however has to date never been examined systematically...
  2. doi request reprint Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis
    I M Omori
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    J Psychopharmacol 23:539-50. 2009
    ..Clinicians should focus on practically or clinically relevant differences including those in side-effect profiles...
  3. doi request reprint Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis
    Norio Watanabe
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya, Japan
    CNS Drugs 24:35-53. 2010
    ..Mirtazapine has a unique mechanism of antidepressant action, and thus is thought to have a different profile of adverse events from that of other antidepressants...
  4. ncbi request reprint Mirtazapine versus other antidepressive agents for depression
    Norio Watanabe
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho cho, Mizuho ku, Nagoya, Aichi, Japan, 467 8601
    Cochrane Database Syst Rev 12:CD006528. 2011
    ..Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice...
  5. ncbi request reprint Fluvoxamine versus other anti-depressive agents for depression
    Ichiro M Omori
    Department of Psychiatry and Cognitive Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Mizuho ku, Nagoya, Japan, 467 8601
    Cochrane Database Syst Rev 3:CD006114. 2010
    ..However, differing side effect profiles were evident. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations, including these differences in side effect profiles...